Genoskin appoints new board member
to strengthen governance
Press release
Genoskin Strengthens Governance with Appointment of Industry Leader Fabrice Bouteille
A strategic milestone reinforcing independence, global growth, and leadership in human-relevant research
A new chapter in Genoskin’s growth journey
Genoskin announces the appointment of Fabrice Bouteille as an independent member of its Board of Directors—marking a pivotal step in the company’s evolution following its $8.7 million (€8 million) Series A financing in September 2025.
As Genoskin accelerates its international expansion and scales its operations, strengthening governance has become a strategic priority. This appointment reflects a strategic decision to align the company’s leadership structure with global best practices—ensuring robust, independent decision-making to support its next phase of growth.
With increasing traction across pharmaceuticals, biotechnology, and especially medical devices, Genoskin is positioning itself at the forefront of human-relevant innovation—where governance, credibility, and scientific rigor are critical differentiators.
Elevating governance to support global ambitions
The addition of an independent Board member underscores Genoskin’s commitment to transparency, objectivity, and high-quality governance.
By reinforcing its Board structure, the company is laying the foundation for:
- Sustainable international expansion across the U.S., Europe and APAC
- Strategic diversification into high-growth sectors like medical devices
- Long-term value creation for partners and stakeholders
This move goes beyond compliance—it is a signal to the market that Genoskin is building a governance model designed to scale with its ambitions.
A proven leader in healthcare & drug delivery
Fabrice Bouteille brings over 20 years of global leadership experience across healthcare, drug delivery, and MedTech.
His expertise includes:
- Injectable drug delivery systems
- Primary packaging and pharmaceutical systems
- Oral and parenteral drug formats
Throughout his career, he has held senior roles spanning commercial strategy and business development across multiple geographies. His experience includes leadership positions within global organizations such as Pfizer, KKR, and Aptar, where he served as Vice President Global Sales for Aptar Pharma Injectables and a member of the Global Leadership Team.
In 2022, he founded his own consulting firm, advising B2B healthcare companies on strategy, commercial performance, and international expansion—expertise that directly aligns with Genoskin’s current trajectory.
A differentiated approach to board independence
In a distinctive approach, Genoskin partnered with APIA (Administrateurs Professionnels Indépendants Associés) to identify and recruit its independent Board members.
This collaboration ensures:
- A rigorous, third-party selection process
- Strong emphasis on experience, independence, and ethics
- Governance that goes beyond traditional investor-driven models
By leveraging APIA’s network of seasoned executives and CEOs, Genoskin reinforces the integrity and objectivity of its Board—an increasingly important factor as the company expands its global footprint.
Leadership perspectives
Pascal Descargues
CEO & Founder, Genoskin
“Fabrice’s appointment is a natural continuation of our Series A and a key step in building a governance framework that matches our global ambitions. His experience and independent perspective will be invaluable as we continue scaling our operations and expanding into key growth areas, including medical devices.”
Fabrice Bouteille
President & Founder, Valexel
“I am honored to join Genoskin’s Board and to support its mission of advancing human-relevant solutions in drug development. Genoskin’s unique technology and dedicated team are already driving cross-continental impact for pharmaceutical and biotech partners. I look forward to contributing to the company’s strategic growth and helping innovators advance safer, more effective therapies.”
Reinforcing trust in human-relevant innovation
With this appointment, Genoskin continues to strengthen its position as a trusted partner for life sciences companies.
At a time when the industry is increasingly seeking predictive, ethical, and human-relevant models, Genoskin’s commitment to strong governance enhances its credibility and ability to deliver high-impact solutions.
This milestone reflects more than leadership expansion—it signals a company building the structure, expertise, and independence required to shape the future of drug and medical device development.
Comments are closed.
